- Home
- NTRB vs MGNX Comparison
NTRB vs MGNX Comparison
Compare NTRB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- MGNX
- Stock Information
- Founded
- NTRB 2016
- MGNX 2000
- Country
- NTRB United States
- MGNX United States
- Employees
- NTRB N/A
- MGNX N/A
- Industry
- NTRB Industrial Specialties
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- MGNX Health Care
- Exchange
- NTRB Nasdaq
- MGNX Nasdaq
- Market Cap
- NTRB 87.2M
- MGNX 99.7M
- IPO Year
- NTRB N/A
- MGNX 2013
- Fundamental
- Price
- NTRB N/A
- MGNX $1.69
- Analyst Decision
- NTRB Buy
- MGNX Hold
- Analyst Count
- NTRB 1
- MGNX 6
- Target Price
- NTRB $13.00
- MGNX $3.20
- AVG Volume (30 Days)
- NTRB 29.0K
- MGNX 548.7K
- Earning Date
- NTRB 12-03-2025
- MGNX 11-04-2025
- Dividend Yield
- NTRB N/A
- MGNX N/A
- EPS Growth
- NTRB N/A
- MGNX N/A
- EPS
- NTRB N/A
- MGNX N/A
- Revenue
- NTRB $2,578,059.00
- MGNX $165,495,000.00
- Revenue This Year
- NTRB $560.75
- MGNX N/A
- Revenue Next Year
- NTRB $588.39
- MGNX N/A
- P/E Ratio
- NTRB N/A
- MGNX N/A
- Revenue Growth
- NTRB 42.92
- MGNX 303.47
- 52 Week Low
- NTRB $2.98
- MGNX $0.99
- 52 Week High
- NTRB $9.42
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- NTRB 53.26
- MGNX 49.58
- Support Level
- NTRB $7.02
- MGNX $1.56
- Resistance Level
- NTRB $8.63
- MGNX $1.83
- Average True Range (ATR)
- NTRB 0.46
- MGNX 0.10
- MACD
- NTRB -0.01
- MGNX -0.01
- Stochastic Oscillator
- NTRB 39.87
- MGNX 46.30
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.